Curis Received Notice of Delisting
Curis (CRIS) received a Nasdaq delisting notice for failing to maintain a minimum $1.00 bid price. The company plans to request a hearing to appeal, but success is not guaranteed. Curis is ineligible for a standard compliance period due to a recent reverse stock split and a one-year Panel Monitor.
How this was made

The 30-second read
Why it matters
The delisting determination is a material corporate action that can erode investor confidence and liquidity, likely driving the share price lower.
Market read
A primary 8‑K filing announcing a delisting notice is a high‑impact corporate event for a listed micro‑cap, warranting immediate trader attention.
What to watch
Potential for a reverse split or capital raise that could restore price above $1, mitigating delisting risk.
Background
Curis Inc. (CRIS) is a clinical‑stage biotech listed on Nasdaq. The company recently completed a 1‑for‑20 reverse split and is under a one‑year Panel Monitor.
Ticker impact
Curis received a Nasdaq delisting determination after its share price stayed below $1 for 30 days, triggering a potential removal from the exchange.
downward pressure as investors price in the risk of delisting and possible loss of liquidity
A primary 8‑K filing announcing a delisting determination is material and new; market participants typically sell on such news.
Market effects
May prompt scrutiny of other low‑price Nasdaq stocks and could tighten listing compliance monitoring.
Limited to U.S. small‑cap and biotech investors; no broader regional effect.
Minimal global impact; primarily a micro‑cap event.
Counterpoint
If Curis successfully appeals the delisting and regains compliance, the stock could rebound on short‑covering.
Key entities
- CompanyCuris Inc.
Biotech firm facing Nasdaq delisting determination.

